More people who can get the flu jab for free should be vaccinated, says NICE
NICE is calling for people who are eligible for free flu vaccination to be offered it at every opportunity.
NICE approves COPD treatment roflumilast for routine NHS use
Thousands of patients to benefit from roflumilast, also known as Daxas, to treat chronic obstructive pulmonary disease (COPD) after NICE says it should be more widely available.
New programme will assess how digital therapies can help treat anxiety and depression
NICE is to start assessing new digital therapies that will help treat more people with anxiety and depression.
New type of treatment for Crohn’s disease is approved by NICE
Following NICE recommendations, patients with Crohn’s disease will have routine NHS access to drug ustekinumab, which offers a new way of treating the condition.
Latest news headlines
-
Kadcyla new deal for breast cancer patients given green light in final draft guidance
A new deal on the breast cancer drug Kadcyla (also called trastuzumab emtansine and made by Roche) means that it can now be recommended for routine funding on the NHS.
15 June 2017
-
NICE to work with partners on developing new ways to measure quality of life across health and social care
NICE is taking part in a project that will examine how quality of life measures used to evaluate healthcare treatments such as drugs can be extended into areas of social care and public health.
13 June 2017
-
NICE to launch new evidence tool for medtech product developers
NICE is launching an online tool to help medtech companies get their products to patients faster.
30 May 2017
-
NICE during the pre-election period
As a public body, NICE is required to follow civil service principles on communicating during the lead up to the general election.
25 April 2017
-
Terminally ill children should have access to around-the-clock homecare, says NICE
NICE has published a draft standard aiming to improve end of life care for children in England.
18 April 2017
-
NICE says head and neck cancer drug is not cost effective
NICE has published draft guidance saying the cost of using nivolumab to treat head and neck cancer is too high for routine NHS use.
11 April 2017